1.
Committed to innovation in GI therapeutics | Movetis
Phase III study data on Movetis' Resolor® (prucalopride) for patients with chronic constipation published in Gut and Alimentary Pharmacology and ...
2.
Privacy Policy | Movetis
Welcome Welcome to www.movetis.com. This site is owned by MOVETIS NV. This Privacy Policy is designed to tell you about our practices regarding collection, ...
3.
Compan y Information
File Format: PDF/Adobe Acrobat - View as HTML Company Profile. Company Information. Our Mission: Through our focus on gastrointestinal (GI) disorders, Movetis seeks to improve the lives of millions of ...
4.
EINDHOVEN: Take the A2/E25 direction Antwerpen/Venlo. Rejoin the ...
File Format: PDF/Adobe Acrobat - View as HTML Take the A2/E25 direction Antwerpen/Venlo. Rejoin the A67/E34 and follow direction Eersel/Antwerpen. After entering Belgium, ...
5.
New Data Presented at UEGW Confirm Effectiveness and Safety of ...
Oct 30, 2007 ... Abstract OP-G-377, UEGW 2007. P. Pare, S. Ferrazzi, W.G. Thompson, et al. ... Am J Gastroenterol 2004;99:750–9. 30/10/2007; Scientific ...
6.
Resolor® (prucalopride) | Movetis
Innovative Compound for Chronic Constipation Our lead compound, prucalopride, is indicated for the treatment of chronic constipation (CC) in patients who ...
7.
8.
9.
10.